We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




IL-1 Regulates Bone Density

By Biotechdaily staff writers
Posted on 14 Sep 2005
Researchers seeking to understand the factors that lead to loss of bone density and development of osteoporosis have found that interleukin-1 (IL-1) produced in the brain is linked to an increase in the number and activity of the multinucleated cells that degrade and reabsorb bone, called osteoclastic cells.

Investigators at the Hebrew University of Jerusalem (Israel) worked with two lines of mice genetically engineered to have defects in brain-generated IL-1. More...
They found that mice of the IL-1rKO line, which lacked the gene for IL-1, had abnormally low bone density. The second line (IL-1raTG) had normal bone density, but could be made to develop osteoporosis by inducing the mice to overexpress human IL-1 receptor antagonist to the central nervous system using the murine glial fibrillary acidic protein promoter. These findings were published in the August 26, 2005, online edition of the Proceedings of the [U.S.] National Academy of Sciences.

"The connection between the brain and the bone structure is a new area of research about which very little is known,” said senior author Professor Itai Bab, director of the bone laboratory at the Hebrew University of Jerusalem. "These new findings regarding the action of interleukin-1 on the breakdown of bone tissue indicate a complex neural system controlling bone structure and point the way towards new revelations in the near future in this area.”




Related Links:
Hebrew University of Jerusalem

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.